EP1846359A4 - Sels d'acide inorganique de sibutramine - Google Patents

Sels d'acide inorganique de sibutramine

Info

Publication number
EP1846359A4
EP1846359A4 EP06700096A EP06700096A EP1846359A4 EP 1846359 A4 EP1846359 A4 EP 1846359A4 EP 06700096 A EP06700096 A EP 06700096A EP 06700096 A EP06700096 A EP 06700096A EP 1846359 A4 EP1846359 A4 EP 1846359A4
Authority
EP
European Patent Office
Prior art keywords
sibutramine
inorganic acid
acid salts
salts
inorganic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06700096A
Other languages
German (de)
English (en)
Other versions
EP1846359A1 (fr
Inventor
Dong Kwon Lim
Eun Young Yang
Jae Kyoung Ko
Kwang Do Choi
Yong Sik Youn
Hea Ran Suh
Chang Ju Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ CheilJedang Corp
Original Assignee
CJ CheilJedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ CheilJedang Corp filed Critical CJ CheilJedang Corp
Publication of EP1846359A1 publication Critical patent/EP1846359A1/fr
Publication of EP1846359A4 publication Critical patent/EP1846359A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/20—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C07C211/24—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP06700096A 2005-01-06 2006-01-06 Sels d'acide inorganique de sibutramine Withdrawn EP1846359A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20050001405 2005-01-06
PCT/KR2006/000073 WO2006073292A1 (fr) 2005-01-06 2006-01-06 Sels d'acide inorganique de sibutramine

Publications (2)

Publication Number Publication Date
EP1846359A1 EP1846359A1 (fr) 2007-10-24
EP1846359A4 true EP1846359A4 (fr) 2010-03-31

Family

ID=36647751

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06700096A Withdrawn EP1846359A4 (fr) 2005-01-06 2006-01-06 Sels d'acide inorganique de sibutramine

Country Status (6)

Country Link
US (1) US7432398B2 (fr)
EP (1) EP1846359A4 (fr)
JP (1) JP2008526836A (fr)
KR (1) KR100830002B1 (fr)
CN (1) CN101098850B (fr)
WO (1) WO2006073292A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060080817A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염
KR100814384B1 (ko) * 2006-02-10 2008-03-18 대화제약 주식회사 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법
KR100800561B1 (ko) * 2006-03-29 2008-02-04 주식회사 삼오제약 시부트라민 술포닐염의 제조방법 및 이를 포함하는비만관련 질환 예방 및 치료용 약학조성물
CN102614179B (zh) 2006-06-16 2015-11-25 H.隆德贝克有限公司 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2，4-二甲基苯基硫烷基)-苯基]哌嗪
CN102786444A (zh) * 2012-07-24 2012-11-21 上海瑞博化学有限公司 一种西布曲明类似物的磺酸盐的制备方法
CN105566327A (zh) * 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
EA202191143A1 (ru) * 2018-10-31 2021-09-10 Ле Лаборатуар Сервье Новая соль ингибитора bcl-2, соответствующая кристаллическая форма, способ их получения и фармацевтические композиции, которые их содержат

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB2184122B (en) 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8704777D0 (en) 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9402641D0 (en) * 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6376551B1 (en) * 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
IL145241A0 (en) * 1999-03-19 2002-06-30 Knoll Gmbh Method of controlling weight gain associated with therapeutic drugs
JP2001050883A (ja) * 1999-08-05 2001-02-23 Akashi Corp 複合機能材料試験機
BR0105486A (pt) 2001-09-27 2003-10-07 Libbs Farmaceutica Ltda Novo composto farmacêutico, seus processos de obtenção e composições farmacêuticas contendo o mesmo
JP4278652B2 (ja) * 2002-10-05 2009-06-17 ハンミ ファーム． シーオー．， エルティーディー． 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
KR20060080817A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
KR20060080818A (ko) * 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 술폰산염

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
CN101098850A (zh) 2008-01-02
KR100830002B1 (ko) 2008-05-15
EP1846359A1 (fr) 2007-10-24
KR20060080899A (ko) 2006-07-11
CN101098850B (zh) 2010-09-15
US7432398B2 (en) 2008-10-07
US20070191489A1 (en) 2007-08-16
WO2006073292A1 (fr) 2006-07-13
JP2008526836A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
HUS2100046I1 (hu) Újfajta hidrogén-szulfát só
EP2065369A4 (fr) Compose d'uree ou sel dudit compose
EP1860098A4 (fr) Nouveau dérivé de l'acide anthranilique ou sel de celui-ci
EP2305641A4 (fr) Composé de sulfonamide ou sel de celui-ci
IL189895A0 (en) Triarylcarboxylic acid derivative
IL205071A0 (en) Azolecarboxamide compound or salt thereof
EP1846359A4 (fr) Sels d'acide inorganique de sibutramine
EP2062902A4 (fr) Sel de lithium
IL196656A0 (en) Sulfonamide compound or salt thereof
HU0600293D0 (en) New rosuvastatine salt
EP1920026A4 (fr) Solution de microgravure amelioree
HK1116417A1 (en) Amino acid derivatives
EP1846360A4 (fr) Sel d'acide sulfonique de sibutramine
ZA200800522B (en) New salt II
IL187655A0 (en) Anthranilic acid derivatives
GB0602780D0 (en) Amino Acid Derivatives
ZA200805701B (en) Salts of styphnic acid
ZA200708153B (en) Phosphate salts of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxycyclohexane
ZA200800515B (en) New Salt I
EP1951694A4 (fr) Formes de sels
GB0506164D0 (en) Purification of salts
GB0512943D0 (en) Indazole-1-acetic acid compounds
GB0523845D0 (en) Novel salts
GB0511000D0 (en) Novel salt
HU0900197D0 (en) New olanzapine salt

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070803

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHOI, KWANG DO11-808, SAMHO APT.

Inventor name: YOUN, YONG SIK105-1004, YEONWONMAEUL BYOKSAN APT.

Inventor name: KO, JAE KYOUNG

Inventor name: KIM, CHANG JU202-102, HYUNDAI I-PARK APT.

Inventor name: YANG, EUN YOUNG334-1207, DUGYEON MAEUL APT.

Inventor name: LIM, DONG KWON109-1301, SAMSUNG RAEMIAN 1-CHA APT

Inventor name: SUH, HEA RAN

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CJ CHEILJEDANG CORPORATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHOI, KWANG DO11-808, SAMHO APT.

Inventor name: YOUN, YONG SIK105-1004, YEONWONMAEUL BYOKSAN APT.

Inventor name: LIM, DONG KWON109-1301, SAMSUNG RAEMIAN 1-CHA APT

Inventor name: SUH, HEA RAN

Inventor name: YANG, EUN YOUNG

Inventor name: KIM, CHANG JU202-102, HYUNDAI I-PARK APT.

Inventor name: KO, JAE KYOUNG

A4 Supplementary search report drawn up and despatched

Effective date: 20100225

17Q First examination report despatched

Effective date: 20100609

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120621